Yunkang Group Limited (2325.HK) Stock Competitors & Peer Comparison
See (2325.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2325.HK | HK$0.65 | +0.00% | 380.5M | -1.40 | -HK$0.46 | N/A |
| 2359.HK | HK$159.20 | +1.27% | 455.9B | 20.18 | HK$7.85 | +1.38% |
| 2268.HK | HK$55.15 | -2.30% | 70.7B | 44.75 | HK$1.25 | N/A |
| 6127.HK | HK$25.10 | +6.54% | 34B | 32.69 | HK$0.76 | +0.56% |
| 9860.HK | HK$3.75 | -6.72% | 2.7B | 85.56 | HK$0.04 | N/A |
| 2251.HK | HK$10.29 | -5.51% | 1B | -5.60 | -HK$1.84 | N/A |
| 8037.HK | HK$0.66 | +1.54% | 644M | -3.23 | -HK$0.20 | N/A |
| 8247.HK | HK$3.12 | +1.30% | 200.6M | -7.61 | -HK$0.41 | N/A |
| 0928.HK | HK$0.07 | +0.00% | 124M | 8.65 | HK$0.01 | N/A |
Stock Comparison
2325.HK vs 2359.HK Comparison July 2026
2325.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2325.HK stands at 380.5M. In comparison, 2359.HK has a market cap of 455.9B. Regarding current trading prices, 2325.HK is priced at HK$0.65, while 2359.HK trades at HK$159.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2325.HK currently has a P/E ratio of -1.40, whereas 2359.HK's P/E ratio is 20.18. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 2359.HK's ROE of +0.27%. Regarding short-term risk, 2325.HK is less volatile compared to 2359.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2325.HK.Check 2359.HK's competition here